Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Melphalan
Dietary Supplement: Ascorbic acid
Drug: PLD
Drug: Prednisone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2014-08-01

Last Posted Date: 2023-10-31

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 45

Registration Number: NCT02206425

Locations: 🇺🇸
James Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸
cCARE Fresno, Fresno, California, United States
🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States

and more 9 locations

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Phase 2

Recruiting

Conditions: Langerhans Cell Histiocytosis

Interventions: Procedure: hematopoietic stem cell transplantation (RIC-HSCT)
Drug: Prednisone
Drug: 2-chlorodeoxyadenosine
Drug: Vinblastine
Biological: Intravenous immunoglobulin
Drug: mercaptopurine
Drug: INDOMETHACIN
Drug: Methotrexate
Drug: Cytosine Arabinoside

First Posted Date: 2014-07-31

Last Posted Date: 2023-03-23

Lead Sponsor: North American Consortium for Histiocytosis

Target Recruit Count: 1400

Registration Number: NCT02205762

Locations: 🇺🇸
Children's Medical Center Dallas, UT Southwestern, Dallas, Texas, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 35 locations

Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).

Phase 3

Completed

Conditions: Pulmonary Sarcoidosis

Interventions: Drug: Hydroxychloroquine + Prednisone
Drug: Prednisone

First Posted Date: 2014-07-25

Last Posted Date: 2014-07-25

Lead Sponsor: University of Milano Bicocca

Target Recruit Count: 94

Registration Number: NCT02200146

Locations: 🇮🇹
Università degli Studi di Milano - Bicocca, Milano, Italy

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Recurrent Burkitt Lymphoma
Refractory Acute Lymphoblastic Leukemia
AIDS-Related Burkitt Lymphoma
Atypical Burkitt/Burkitt-Like Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent Acute Lymphoblastic Leukemia
Refractory Burkitt Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2014-07-24

Last Posted Date: 2024-06-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT02199184

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Velcade
Drug: Melphalan
Drug: Prednisone
Drug: Daratumumab IV
Drug: Dexamethasone
Drug: Daratumumab SC

First Posted Date: 2014-07-21

Last Posted Date: 2024-12-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 706

Registration Number: NCT02195479

Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions

Phase 4

Conditions: Pituitary Neoplasms
Craniopharyngiomas

Interventions: Drug: Hydrocortisone
Drug: Prednisone

First Posted Date: 2014-07-15

Last Posted Date: 2014-07-15

Lead Sponsor: West China Hospital

Target Recruit Count: 100

Registration Number: NCT02190994

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

Phase 1

Terminated

Conditions: Liver Transplantation

Interventions: Biological: Anti-Thymocyte Globulin - Rabbit
Biological: darTreg Infusion
Drug: Everolimus
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Drug: Anti-Infective Prophylaxis
Drug: Prednisone
Procedure: Blood draws
Drug: Acetaminophen
Procedure: Liver biopsies
Drug: Diphenhydramine
Procedure: Liver transplantation
Procedure: Leukapheresis

First Posted Date: 2014-07-14

Last Posted Date: 2020-09-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15

Registration Number: NCT02188719

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Nevirapine
Drug: Prednisone

First Posted Date: 2014-07-09

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 138

Registration Number: NCT02184299

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

Phase 1

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Prednisone
Drug: LDE225

First Posted Date: 2014-07-08

Last Posted Date: 2019-06-19

Lead Sponsor: Martin Gutierrez

Registration Number: NCT02182622

Locations: 🇺🇸
John Theurer Cancer @ HackensackUMC, Hackensack, New Jersey, United States

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Phase 3

Active, not recruiting

Conditions: Ann Arbor Stage IIIB Hodgkin Lymphoma
Childhood Hodgkin Lymphoma
Ann Arbor Stage IVB Hodgkin Lymphoma
Classic Hodgkin Lymphoma
Ann Arbor Stage IIB Hodgkin Lymphoma
Ann Arbor Stage IVA Hodgkin Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Methylprednisolone
Other: Pharmacological Study
Drug: Prednisone
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Vincristine Sulfate

First Posted Date: 2014-06-18

Last Posted Date: 2024-12-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 600

Registration Number: NCT02166463

Locations: 🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
🇺🇸
Corewell Health Children's, Royal Oak, Michigan, United States
🇺🇸
Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States

and more 196 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy